Phase I/II ARROW trial results show that pralsetinib, a highly selective RET inhibitor, was well-tolerated and demonstrated robust, durable responses in patients with RET fusion-positive cancers regardless of tumor type.
The University of Texas MD Anderson Cancer Center launched its Institute for Cell Therapy Discovery & Innovation.
